相关实验视频
Updated: Jun 29, 2025
05:34
5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
562
脏AL Amyloidosis:关于诊断,分期和管理的最新信息
Areez Shafqat1, Hassan Elmaleh2, Ali Mushtaq3
1College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia.
Journal of clinical medicine
|March 28, 2024
概括
轻链 (AL) 氨基粉症是由异常蛋白质引起的,会损害心脏和脏等器官. 新的治疗方法显示出清除粉样纤维素和改善结果的希望,特别是在脏AL粉样化症中.
科学领域:
- 血液学 血液学 血液学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 免疫学 免疫学 免疫学
背景情况:
- 粉样性粉样性粉样性粉样性粉样性粉样性粉样性粉样性粉样性粉样性粉样性粉样性粉样性粉样性粉样性粉样性粉样性粉样性粉样性粉样性粉样性粉样性粉样性粉样性粉样性粉样性粉样性粉样性粉样性粉样性粉样性粉样性粉样性粉样性粉样性粉样性粉样性粉样性粉样性粉样性粉样性粉样性粉样性粉样性粉样性粉样性粉样性粉样性粉样性粉样性粉样性粉样性粉样性粉样性粉样性.
- 非特异性症状导致诊断延迟和疾病的晚期呈现.
- 脏干扰是常见的,并影响患者的预后,像Pavia脏分期预测进展这样的模型.
研究的目的:
- 提供对当前诊断,分期,治疗和监测AL氨基粉症的策略的全面审查.
- 强调脏参与在AL粉样性粉症管理中的重要性.
- 要突出最近在治疗方法的进步对AL粉样性粉症.
主要方法:
- 关于AL氨基粉症诊断,分期和治疗的现有文献的综述.
- 对具有里程碑意义的临床试验的分析,包括ANDROMEDA试验.
- 讨论新兴的治疗方式和生物标志物.
主要成果:
- 在ANDROMEDA试验中,达拉图穆马布加上循环胺,博特佐米布和德克萨美沙 (Dara-CyBorD) 证明了对脏反应和降低死亡率的有效性.
- 这种t(11:14) 转位可以预测对venetoclax (抗BCL2疗法) 的反应.
- 新型抗纤维素免疫疗法正在出现,用于粉样纤维素清除,尽管仍在临床试验中.
结论:
- 有效管理AL粉样粉症需要综合的诊断,分期和治疗策略,重点关注功能.
- 达拉-CyBorD是一种有效的治疗方案,但对于复发/耐药病例的治疗仍然很复杂.
- 新兴疗法为纤维素清除提供了新的希望,并改善了ALamyloidosis患者的治疗结果.
相关概念视频
01:11Renal Failure: Dose Adjustments
88
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
88
03:03Amyloid Fibrils
5.1K
5.1K
01:17Factors Affecting Renal Clearance: Renal Impairment
91
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
91
01:26Alzheimer's Disease: Overview
469
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
469